No quarterly revenue total was found in Lakewood-Amedex Biotherapeutics Inc.'s SEC filings.
Lakewood-Amedex Biotherapeutics Inc. (LABT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $4.6 million in cash and investments and $101,619 in total debt.
Revenue
—
Net income
$-3.77M
-308.5% vs prior quarter
Operating cash flow
$-2.10M
-501.7% vs prior quarter
Free cash flow
—
EPS
$-2.75
-1275.0% vs prior quarter
Dividend per share
None
Shares outstanding
2.37M
-66.1% vs prior quarter
Net cash
$4.48M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LABT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- University Park, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Operating income | -$3.8M | -$886,750 |
| Net income | -$3.8M | -$923,291 |
| Diluted EPS | -$2.75 | -$0.20 |
| Operating cash flow | -$2.1M | -$349,691 |
| Total assets | $5.0M | $196,343 |
| Total liabilities | $628,926 | $3.0M |
| Stockholders' equity | $4.3M | -$2.8M |
| Cash and investments | $4.6M | $11,709 |
| Total debt | $101,619 | $131,339 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 15, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jun 17, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 22, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 28, 2026 | Apr 24, 2026 |
All 44 Lakewood-Amedex Biotherapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.